Developer docs
API playgroundTry for free, no card

Search company profiles

Fuse Diagnostics

Full company profile

uuid0000khy

Namestring
Fuse Diagnostics
Legal namestring
Fuse Diagnostics Limited
Websiteurl
fuse-dx.com
Company typeenum
Private
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostic tests, point-of-need diagnostics, rapid pathogen testing, mycoplasma detection, instrument-free diagnostics
Industry4 codes
PRIMARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYAFALAEAK
Rapid On-Site Environmental Testing Kits & Instruments (Lateral Flow, PCR, ATP Devices)
Agriculture & Food Production/Food Safety, Testing & Certification/Environmental Monitoring & Hygiene Verification (Swabs, ATP, Pathogen Monitoring)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Test Devices and Disposables
TypeHardware Sales
Description

Fuse generates revenue from the sale of its diagnostic test devices and single-use disposable test kits. The Flip and Apex platforms are designed as low-cost, disposable, single-use products. Revenue is derived from product sales to end users in industrial, food, water, clinical, and veterinary sectors through direct sales and distribution partners.

fuse-dx.com
2Distribution Partnership Revenue
TypeTransaction Fee
Description

Revenue flows through distribution partnerships with Stratech Scientific (UK & Ireland) and CliniSciences (major European countries), where distributors purchase and resell Fuse products to end customers.

fuse-dx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others
Pricing details1 tier
1Flip and Apex diagnostic test products are sold as single-use, low-cost disposable devices. Specific pricing tiers are not publicly disclosed.
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed. Quote-based / Not publicly disclosed.

fuse-dx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Flip
Description

A versatile platform for rapid onsite testing across Industry, Food and Veterinary sectors. Flip delivers definitive laboratory quality results in an easy-to-use, low-cost device without any specialist equipment. The first product, Flip Mycoplasma, detects cell culture contamination with laboratory PCR quality results in just 12 minutes.

fuse-dx.com
+1 more record
Core offering1 text field

Fuse Diagnostics develops and sells proprietary, instrument-free, disposable molecular diagnostic test devices built on its multianalytic amplification chemistry. The Flip product range delivers rapid, laboratory-quality pathogen testing for industrial, food, water, and veterinary settings, while the Apex product range is designed for point-of-care clinical diagnostics such as sexually transmitted and respiratory infections. The first commercial product, Flip Mycoplasma, detects mycoplasma contamination in cell cultures with PCR-quality results in 12 minutes using a visual read-out and no specialist equipment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Flip Mycoplasma delivers laboratory PCR-quality results in 12 minutes
+2 more records
Product overview1 text field

Fuse Diagnostics offers two distinct diagnostic platforms: Flip and Apex. Flip is a versatile platform for rapid point-of-need testing in industrial, food, water, and veterinary sectors, delivering laboratory-quality results in a low-cost, disposable device without specialist equipment. Apex is designed for point-of-care clinical diagnostics, targeting applications such as respiratory and sexually transmitted infections. The Flip product range includes Flip Mycoplasma (launched), and upcoming tests for Legionella and Avian Influenza. Apex CT/NG targets Chlamydia and Gonorrhoea diagnostics. Both platforms leverage proprietary multianalytic amplification chemistries for rapid results.

Product and service2 records
1Flip Mycoplasma
CategoryMolecular diagnostics - mycoplasma contamination testing
Description

First product in the Flip product range; a disposable, instrument-free molecular test that detects mycoplasma contamination in cell cultures in 12 minutes with laboratory PCR-quality accuracy and a clear visual read-out, designed for industrial bioprocessing QC, food, water, and veterinary users.

2Flip Nest
CategoryDiagnostic accessory
Description

USB-C powered accessory designed for use with Flip tests, enabling rapid molecular-quality testing in any location without mains power or specialist instrumentation.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-23
Description

Fuse Diagnostics signed a distribution agreement with CliniSciences for the launch of Flip Mycoplasma in Europe. The agreement covers major European countries including France, Germany, Spain, and Italy. CliniSciences is a leading European distributor for life science and diagnostic labs, acting as a key player linking manufacturers with researchers in Europe and North America.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-28
Description

Fuse Diagnostics and Stratech Scientific formed a strategic distribution partnership for the commercialisation of Flip Mycoplasma in the UK and Ireland. Stratech is a leading life science company with 40 years of experience, providing reagents and solutions to academic research, pharmaceutical companies, and clinical diagnostics. Flip Mycoplasma is also available for purchase through Stratech's catalogue.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based molecular diagnostics company using CRISPR-based amplification for rapid, instrument-free nucleic acid detection. Directly comparable because it acquired Sense Biodetection (Fuse founders' prior company) and operates in the same rapid, decentralized molecular diagnostic category.

TypeDirect peer
Description

UK-based developer of the Q-POC rapid molecular point-of-care diagnostic platform. Directly comparable as a similarly-sized UK molecular POCT company targeting decentralised, near-patient testing for infectious disease.

TypeDirect peer
Description

Developer of the io molecular platform for rapid, instrument-based CT/NG STI testing at the point of care. Directly comparable because it targets the same clinical use case as Fuse's Apex CT/NG assay (rapid molecular STI diagnostics).

TypeDirect peer
Description

UK-based developer of a portable, rapid molecular testing platform (Cube). Directly comparable as a small UK molecular POCT company delivering laboratory-grade results in a compact, near-patient format.

TypeDirect peer
Description

US molecular diagnostics company with T2 Magnetic Resonance-based rapid panels for sepsis and other infections. Comparable as a small-cap molecular diagnostics company pursuing rapid, decentralised detection of pathogens without traditional lab workflows.

TypeBroad incumbent
Description

Subsidiary of Danaher and the established leader in molecular POCT with the GeneXpert platform. Broad incumbent offering overlapping molecular diagnostic capabilities across infectious disease, but as part of a much larger portfolio and reliant on a proprietary instrument.

7Abbott Diagnostics
TypeBroad incumbent
Description

Global diagnostics giant with rapid molecular platforms including ID NOW. Broad incumbent operating across immunoassay, molecular and POC diagnostics with deep regulatory clearances and global hospital penetration.

TypeBroad incumbent
Description

US diagnostics company with the Panther molecular system widely used for STI screening including CT/NG. Broad incumbent in women's health and molecular diagnostics with large installed base and FDA-cleared assays overlapping Fuse's Apex CT/NG target use case.

TypeBroad incumbent
Description

French in vitro diagnostics company with molecular (BioFire FilmArray), industrial microbiology and food pathogen testing product lines. Broad incumbent spanning clinical and industrial microbiology - the same verticals Fuse addresses with Flip and Apex.

TypeOthers
Description

Fuse founders' previous company, which developed the Veros instrument-free rapid molecular COVID-19 test and was acquired by Sherlock Biosciences in 2023. Relevant as the technological predecessor and proof point for Fuse's founding team, though it no longer operates independently.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fuse Diagnostics

Molecular Diagnosticsfuse-dx.com

Fuse Diagnostics firmographics

Firmographics
Name
Fuse Diagnostics
Legal name
Fuse Diagnostics Limited
Website
https://fuse-dx.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Fuse Diagnostics industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYAFALAEAK
Rapid On-Site Environmental Testing Kits & Instruments (Lateral Flow, PCR, ATP Devices)
Agriculture & Food Production/Food Safety, Testing & Certification/Environmental Monitoring & Hygiene Verification (Swabs, ATP, Pathogen Monitoring)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Molecular diagnostic tests
  • Point-of-need diagnostics
  • Rapid pathogen testing
  • Mycoplasma detection
  • Instrument-free diagnostics

Where Fuse Diagnostics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Fuse Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

  1. Diagnostic Test Devices and Disposables: Fuse generates revenue from the sale of its diagnostic test devices and single-use disposable test kits. The Flip and Apex platforms are designed as low-cost, disposable, single-use products. Revenue is derived from product sales to end users in industrial, food, water, clinical, and veterinary sectors through direct sales and distribution partners.
  2. Distribution Partnership Revenue: Revenue flows through distribution partnerships with Stratech Scientific (UK & Ireland) and CliniSciences (major European countries), where distributors purchase and resell Fuse products to end customers.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goFlip and Apex diagnostic test products are sold as single-use, low-cost disposable devices. Specific pricing tiers are not publicly disclosed.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels3 records

Fuse Diagnostics product offering

Product offering

Core offering

Fuse Diagnostics develops and sells proprietary, instrument-free, disposable molecular diagnostic test devices built on its multianalytic amplification chemistry. The Flip product range delivers rapid, laboratory-quality pathogen testing for industrial, food, water, and veterinary settings, while the Apex product range is designed for point-of-care clinical diagnostics such as sexually transmitted and respiratory infections. The first commercial product, Flip Mycoplasma, detects mycoplasma contamination in cell cultures with PCR-quality results in 12 minutes using a visual read-out and no specialist equipment.

Product overview

Fuse Diagnostics offers two distinct diagnostic platforms: Flip and Apex. Flip is a versatile platform for rapid point-of-need testing in industrial, food, water, and veterinary sectors, delivering laboratory-quality results in a low-cost, disposable device without specialist equipment. Apex is designed for point-of-care clinical diagnostics, targeting applications such as respiratory and sexually transmitted infections. The Flip product range includes Flip Mycoplasma (launched), and upcoming tests for Legionella and Avian Influenza. Apex CT/NG targets Chlamydia and Gonorrhoea diagnostics. Both platforms leverage proprietary multianalytic amplification chemistries for rapid results.

Differentiator

Problem solved

Functional benefit

Brands

  • Flip: A versatile platform for rapid onsite testing across Industry, Food and Veterinary sectors. Flip delivers definitive laboratory quality results in an easy-to-use, low-cost device without any specialist equipment. The first product, Flip Mycoplasma, detects cell culture contamination with laboratory PCR quality results in just 12 minutes.
  • Apex

Products and services

  • Flip Mycoplasma First product in the Flip product range; a disposable, instrument-free molecular test that detects mycoplasma contamination in cell cultures in 12 minutes with laboratory PCR-quality accuracy and a clear visual read-out, designed for industrial bioprocessing QC, food, water, and veterinary users.
  • Flip Nest USB-C powered accessory designed for use with Flip tests, enabling rapid molecular-quality testing in any location without mains power or specialist instrumentation.

Quantifiable outcome

  • Flip Mycoplasma delivers laboratory PCR-quality results in 12 minutes
  • +2 more outcomes

Companies that use Fuse Diagnostics

Customer profile

Segments3 records

Ideal customer profiles3 records

Fuse Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Fuse Diagnostics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • CliniSciencescoreChannel Partner/ Reseller/ Distributor · 23 September 2025Fuse Diagnostics signed a distribution agreement with CliniSciences for the launch of Flip Mycoplasma in Europe. The agreement covers major European countries including France, Germany, Spain, and Italy. CliniSciences is a leading European distributor for life science and diagnostic labs, acting as a key player linking manufacturers with researchers in Europe and North America.
  • Stratech ScientificcoreChannel Partner/ Reseller/ Distributor · 28 August 2025Fuse Diagnostics and Stratech Scientific formed a strategic distribution partnership for the commercialisation of Flip Mycoplasma in the UK and Ireland. Stratech is a leading life science company with 40 years of experience, providing reagents and solutions to academic research, pharmaceutical companies, and clinical diagnostics. Flip Mycoplasma is also available for purchase through Stratech's catalogue.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Fuse Diagnostics competitors and assessment

Company assessment

Direct peers

  • Sherlock Biosciences: US-based molecular diagnostics company using CRISPR-based amplification for rapid, instrument-free nucleic acid detection. Directly comparable because it acquired Sense Biodetection (Fuse founders' prior company) and operates in the same rapid, decentralized molecular diagnostic category.
  • QuantuMDx: UK-based developer of the Q-POC rapid molecular point-of-care diagnostic platform. Directly comparable as a similarly-sized UK molecular POCT company targeting decentralised, near-patient testing for infectious disease.
  • Binx Health: Developer of the io molecular platform for rapid, instrument-based CT/NG STI testing at the point of care. Directly comparable because it targets the same clinical use case as Fuse's Apex CT/NG assay (rapid molecular STI diagnostics).
  • Genomadix: UK-based developer of a portable, rapid molecular testing platform (Cube). Directly comparable as a small UK molecular POCT company delivering laboratory-grade results in a compact, near-patient format.
  • T2 Biosystems: US molecular diagnostics company with T2 Magnetic Resonance-based rapid panels for sepsis and other infections. Comparable as a small-cap molecular diagnostics company pursuing rapid, decentralised detection of pathogens without traditional lab workflows.

Broad incumbents

  • Cepheid (Danaher): Subsidiary of Danaher and the established leader in molecular POCT with the GeneXpert platform. Broad incumbent offering overlapping molecular diagnostic capabilities across infectious disease, but as part of a much larger portfolio and reliant on a proprietary instrument.
  • Abbott Diagnostics: Global diagnostics giant with rapid molecular platforms including ID NOW. Broad incumbent operating across immunoassay, molecular and POC diagnostics with deep regulatory clearances and global hospital penetration.
  • Hologic: US diagnostics company with the Panther molecular system widely used for STI screening including CT/NG. Broad incumbent in women's health and molecular diagnostics with large installed base and FDA-cleared assays overlapping Fuse's Apex CT/NG target use case.
  • bioMérieux: French in vitro diagnostics company with molecular (BioFire FilmArray), industrial microbiology and food pathogen testing product lines. Broad incumbent spanning clinical and industrial microbiology - the same verticals Fuse addresses with Flip and Apex.

Others

  • Sense Biodetection (acquired by Sherlock Biosciences): Fuse founders' previous company, which developed the Veros instrument-free rapid molecular COVID-19 test and was acquired by Sherlock Biosciences in 2023. Relevant as the technological predecessor and proof point for Fuse's founding team, though it no longer operates independently.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Fuse Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fuse Diagnostics leadership team

Management profile

Number of profiles

Profiles2 records

Fuse Diagnostics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fuse Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fuse Diagnostics

What does Fuse Diagnostics do?

Fuse Diagnostics develops and sells proprietary, instrument-free, disposable molecular diagnostic test devices built on its multianalytic amplification chemistry. The Flip product range delivers rapid, laboratory-quality pathogen testing for industrial, food, water, and veterinary settings, while the Apex product range is designed for point-of-care clinical diagnostics such as sexually transmitted and respiratory infections. The first commercial product, Flip Mycoplasma, detects mycoplasma contamination in cell cultures with PCR-quality results in 12 minutes using a visual read-out and no specialist equipment.

Is Fuse Diagnostics a public or private company?

Fuse Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Fuse Diagnostics founded?

Fuse Diagnostics was founded in 2022. It employs 11 to 50 people.

Where is Fuse Diagnostics based?

Fuse Diagnostics is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Fuse Diagnostics make money?

Two revenue lines are on record. Diagnostic Test Devices and Disposables are the primary driver. The others are distribution Partnership Revenue.

Who are Fuse Diagnostics's main competitors?

Direct peers on record are Sherlock Biosciences, QuantuMDx, Binx Health, Genomadix and T2 Biosystems. Broad incumbents are Cepheid (Danaher), Abbott Diagnostics, Hologic and bioMérieux. Sense Biodetection (acquired by Sherlock Biosciences) is listed as an others.

Does Fuse Diagnostics have an API?

No public API is recorded for Fuse Diagnostics.

What industry is Fuse Diagnostics in?

Fuse Diagnostics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges), with a secondary code of HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InsidermediaMolecular diagnostics developer raises £1m to scale testing platformFuse Diagnostics raised £1m led by The FSE Group to accelerate commercialisation and expand manufacturing at its Cambridge headquarters. The funding will support its Flip product portfolio across six sectors, including life sciences, food safety, and veterinary diagnostics. The company aims to make laboratory-quality molecular diagnostics accessible in environments needing rapid testing.UK Business Angels AssociationFuse Diagnostics raises £1 million to scale rapid point-of-need molecular testing platformFuse Diagnostics raised £1 million led by The FSE Group to accelerate commercialisation of its Flip molecular testing platform. The funding will expand manufacturing and support assay development across six sectors, including life sciences and food safety.The FSE GroupFuse Diagnostics raises £1 millionFuse Diagnostics raised £1 million led by The FSE Group to accelerate commercialisation of its Flip molecular diagnostics platform. The funding will expand manufacturing and support assay development across six sectors, including life sciences and food safety.StartupmagFuse Diagnostics raises £1m led by FSE Group with Cambridge Capital GroupFuse Diagnostics raised £1m in a pre-seed round led by FSE Group with Cambridge Capital Group to commercialise its Flip molecular diagnostics platform. The funding will accelerate assay development and validation across industrial and environmental markets, including food safety, water monitoring, and bioprocessing.Fuse-DxFuse Raises £1 million to Scale Rapid Point-of-Need Molecular Testing Platform — FuseFuse Diagnostics raised £1 million led by The FSE Group to accelerate commercialisation of its Flip molecular testing platform. The funding will expand manufacturing in Cambridge and support assay development across six sectors. The company aims to make rapid, laboratory-quality diagnostics accessible outside specialist labs.Cambridge NetworkFuse Diagnostics raises £1 million to scale rapid point-of-need molecular testing platformFuse Diagnostics raised £1 million led by The FSE Group to accelerate commercialisation of its Flip molecular testing platform. The funding will expand manufacturing and support assay development across six sectors, including life sciences and food safety.StartupSeekerFuse Diagnostics - Funding: $2M+Fuse Diagnostics, a Cambridge-based startup founded in 2022, has raised $2.65 million in funding to support its rapid, low-cost diagnostic testing technology. The company aims to provide lab-quality results in decentralized settings, addressing logistical bottlenecks associated with traditional centralized laboratory testing.Carb-XCARB-X funds Fuse Diagnostics to develop innovative, instrument-free diagnostic for chlamydia and drug-resistant gonorrheaCARB-X will award up to US$1 million to Fuse Diagnostics to demonstrate proof-of-concept and feasibility of its Apex CT/NG test, an instrument-free diagnostic for Chlamydia trachomatis and Neisseria gonorrhoeae. The award funds performance testing on clinical samples, with development of the rapid, low-cost assay to follow. Fuse is the third diagnostic to receive a CARB-X grant from the 2022-2023 funding call.Water MagazineFuse raises £1.6m seed funding to develop innovative point-of-need diagnostic testsFuse Diagnostics raised £1.6m in seed funding from angel investors and Innovate UK. The funds will develop rapid, low-cost diagnostic tests for industrial, food, water, clinical, and veterinary applications. The company is developing two platforms, Flip and Apex, targeting mycoplasma contamination and other pathogen detection.